Mirati Therapeutics Inc Stock, NASDAQ:MRTX
3545 Cray Court, Suite 200, San Diego, California 92121
United States of America
Number of Employees: 201
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company, which engages in the development of novel therapeutics. The firm's products targets the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.